房颤合并稳定冠心病:抗凝单药与联合抗血小板治疗的荟萃分析
该系统评价与荟萃分析纳入4项随机对照试验共4092例房颤合并稳定冠心病患者,比较口服抗凝单药与口服抗凝联合单抗血小板治疗的有效性和安全性。结果显示两组主要有效性复合终点无统计学显著差异,但口服抗凝单药显著降低大出血风险。
要点
- 房颤合并稳定冠心病患者,口服抗凝单药与联合抗血小板治疗的有效性终点无显著差异
- 口服抗凝单药较联合治疗显著降低大出血风险
- 亚组分析提示男性和糖尿病患者中出血减少幅度可能更大
核心结论
- 在房颤合并稳定冠心病患者中,口服抗凝单药相比口服抗凝联合单抗血小板治疗未显著增加缺血事件风险,且显著降低出血风险。
研究设计与样本
- 系统检索PubMed、Embase和ClinicalTrials.gov至2024年9月9日,纳入4项随机对照试验共4092例患者(2项使用艾多沙班,1项使用利伐沙班,1项使用任何口服抗凝药;平均年龄73.9岁,女性20.1%)。
- 中位随访时间12至30个月,总体估计加权平均随访21.9个月。
主要发现
- 主要有效性复合终点(心肌梗死、缺血性卒中、系统性栓塞或死亡)在口服抗凝单药组为7.3%,联合治疗组为8.2%(HR 0.90,95%CI 0.72-1.12)。
- 心肌梗死发生率单药组1.0% vs 联合组0.7%(HR 1.51,95%CI 0.75-3.04)。
- 缺血性卒中发生率单药组1.9% vs 联合组2.1%(HR 0.89,95%CI 0.57-1.37)。
- 全因死亡单药组4.2% vs 联合组5.3%(HR 0.94,95%CI 0.49-1.80);心血管死亡单药组2.4% vs 联合组3.0%(HR 0.79,95%CI 0.54-1.15)。
- 大出血单药组3.3% vs 联合组5.7%(HR 0.59,95%CI 0.44-0.79)。
关键数值与推荐
- 有效性亚组分析未显示显著交互作用;出血减少幅度在男性(P交互=0.03)和糖尿病患者(P交互=0.04)中可能更大。
临床怎么用
- 对于房颤合并稳定冠心病患者,口服抗凝单药治疗可作为减少出血风险的合理选择,且不显著增加缺血事件。
局限性
- 各随机对照试验报告结果存在差异且未针对有效性终点进行功效计算;随访时间中位12至30个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal long-term antithrombotic strategy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains uncertain. Individual randomized controlled trials (RCTs) had variations in their reported results and were not powered for effectiveness outcomes. OBJECTIVES: This study aimed to pool the results of RCTs comparing the effectiveness and safety of oral anticoagulation (OAC) monotherapy vs OAC plus single antiplatelet therapy (SAPT) in patients with AF and stable CAD. METHODS: We systematically searched PubMed, Embase, and ClinicalTrials.gov until September 09, 2024. The primary effectiveness outcome was a composite of myocardial infarction, ischemic stroke, systemic embolism, or death. The primary safety outcome was major bleeding. We obtained unpublished results from principal investigators of the included RCTs, as needed, to calculate pooled HRs and 95% CIs and to perform prespecified subgroup analyses. RESULTS: Among 690 screened records, 4 RCTs with 4,092 randomized patients were included (2 using edoxaban, 1 using rivaroxaban, and 1 using any oral anticoagulant; mean age 73.9 years, 20.1% women). The median follow-up durations ranged from 12 to 30 months (overall estimated weighted mean follow-up of 21.9 months). There were no statistically significant differences between OAC monotherapy vs OAC plus SAPT in the primary effectiveness outcome (7.3% vs 8.2%; HR: 0.90; 95% CI: 0.72-1.12), myocardial infarction (1.0% vs 0.7%; HR: 1.51; 95% CI: 0.75-3.04), ischemic stroke (1.9% vs 2.1%; HR: 0.89; 95% CI: 0.57-1.37), all-cause death (4.2% vs 5.3%; HR: 0.94; 95% CI: 0.49-1.80), or cardiovascular death (2.4% vs 3.0%; HR: 0.79; 95% CI: 0.54-1.15). OAC monotherapy was associated with a lower risk of major bleeding than OAC plus SAPT (3.3% vs 5.7%; HR: 0.59; 95% CI: 0.44-0.79). Subgroup analyses did not show significant interactions for effectiveness but suggested that the magnitude of bleeding reduction may be greater among men (Pinteraction = 0.03) and among patients with diabetes mellitus (Pinteraction = 0.04). CONCLUSIONS: In patients with AF and stable CAD, OAC monotherapy, compared with OAC plus SAPT, was not associated with a statistically significant increased risk of ischemic events but resulted in a significantly reduced risk of bleeding.
引用
- Rashedi, Keykhaei, Sato, et al. Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2025. PMID: 39918465. doi:10.1016/j.jacc.2024.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。